Teresa Amaral, Core Member EMA SAG Oncology at European Medicines Agency, shared a post on LinkedIn:
”Yesterday, during the Arbeitsgemeinschaft Dermatologische Onkologie (ADO) e.V. congress, I had the chance to talk about the journey of the Merlin Assay for Melanoma from the discovery, to its predictive and prognostic value, highlighting the work done by our team in Tuebingen – Efi (Eftychia) Chatziioannou, Heike Niessner (thanks for the pics) Tobias Sinnberg.
Thomas Eigentler and Dr. Karl Georg Simon Frey discussed clinical cases from the daily practice where these types of assays could be of use.
The MerlinForMe program in Germany will provide patients and their doctors with the opportunity to request the assay when deemed adequate during this transition period. More information here.
Thanks for the excellent collaboration, SkylineDx BV, and to all of those attending the event. Joana Schroth, Younes Salahdine, Iron Bridge GmbH team, Francisco Meraz Torres, Konstatinos Lallas, Melanie Peter, Fabienne Schönenberger, Hello Healthcare Berlin GmbH.”
More posts featuring Teresa Amaral on OncoDaily.
